2 results
Approved WMOCompleted
To provide preliminary technical feasibility, safety and efficacy data foreCLIPs Family of products.
Not approvedWill not start
The primary objective of this study is to evaluate the proportion of patients achieving FXI inhibition * 80% at trough (Day 91) after monthly dosing at 3 dose levels of MAA868.